Cargando…

Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations occur in about 50% of Asian patients with non‐small cell lung cancer (NSCLC). Patients with advanced NSCLC and EGFR mutations derive clinical benefit from treatment with EGFR‐tyrosine kinase inhibitors (TKIs). This study assessed the effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Shuyang, Zhi, Xiuyi, Wang, Ruotian, Qian, Kun, Hu, Mu, Zhang, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130296/ https://www.ncbi.nlm.nih.gov/pubmed/27766784 http://dx.doi.org/10.1111/1759-7714.12365

Ejemplares similares

Lung adenocarcinoma harboring rare epidermal growth factor receptor L858R and V834L mutations treated with icotinib: A case report
por: Zhai, Shu-Sen, et al.
Publicado: (2020)

Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib
por: Zhu, Zhouyu, et al.
Publicado: (2016)

Clinical and radiological predictors of epidermal growth factor receptor mutation in nonsmall cell lung cancer
por: Dang, Yutao, et al.
Publicado: (2020)

Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
por: Sun, Sheng-Jie, et al.
Publicado: (2022)

Icotinib versus Cisplatin Plus Docetaxel as Adjuvant Chemotherapy in Patients with Stage II (N1+) Non-Small Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study
por: Pan, Saibo, et al.
Publicado: (2021)

Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi‐center study
por: Lei, Lei, et al.
Publicado: (2020)

Response to Icotinib Plus Chemotherapy in Pulmonary Atypical Carcinoid Harboring the EGFR L858R Mutation: A Brief Report
por: Chen, Yu-Qing, et al.
Publicado: (2021)

Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone
por: Xu, Yunhua, et al.
Publicado: (2020)

Associations between epidermal growth factor receptor mutations and histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification in Chinese patients
por: Wang, Tengteng, et al.
Publicado: (2017)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
por: Liang, Wenhua, et al.
Publicado: (2014)

Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study
por: Zeng, Ziqing, et al.
Publicado: (2020)

Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes
por: Wang, Tao, et al.
Publicado: (2016)

The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis
por: Wang, Lulu, et al.
Publicado: (2018)

Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy
por: Feng, Siyang, et al.
Publicado: (2015)

Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation
por: Xia, Pinghui, et al.
Publicado: (2018)

Icotinib combined with rapamycin in a renal transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer: A case report
por: ZHAO, QIONG, et al.
Publicado: (2014)

Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study
por: Xu, Jianping, et al.
Publicado: (2017)

Real world study for the concordance between IBM Watson for Oncology and clinical practice in advanced non‐small cell lung cancer patients at a lung cancer center in China
por: Yao, Shuyang, et al.
Publicado: (2020)

Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report
por: Zhou, Bin, et al.
Publicado: (2022)

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
por: Wu, Shang-Gin, et al.
Publicado: (2020)

The management of postoperative recurrence of non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutation: what is the best way?
por: Adachi, Hiroyuki, et al.
Publicado: (2022)

Complete remission through icotinib treatment in Non-small cell lung cancer epidermal growth factor receptor mutation patient with brain metastasis: A case report
por: Wang, Tao, et al.
Publicado: (2016)

Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC
por: Zhang, Ningning, et al.
Publicado: (2019)

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial
por: Liu, Yu-Tao, et al.
Publicado: (2020)

Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation
por: Chen, Jianxin, et al.
Publicado: (2022)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study
por: Chen, Xiaofeng, et al.
Publicado: (2014)

Lung cancer patients harboring epidermal growth factor receptor mutation among those infected by human immunodeficiency virus
por: Okuma, Yusuke, et al.
Publicado: (2014)

Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine
por: Akiyama, Norimichi, et al.
Publicado: (2017)

Analysis of non-small cell lung cancer with miliary lung metastasis in patients harboring epidermal growth factor receptor mutations
por: Chang, Ming-Hung, et al.
Publicado: (2022)

Efficacy of icotinib in advanced lung squamous cell carcinoma
por: Liang, Shuai, et al.
Publicado: (2018)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials
por: Zhao, Ning, et al.
Publicado: (2023)

Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report
por: SUN, QIONG, et al.
Publicado: (2014)

Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation
por: Ko, How-Wen, et al.
Publicado: (2022)

Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib
por: Kanaoka, Kensuke, et al.
Publicado: (2023)

An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
por: Zhang, Ying, et al.
Publicado: (2015)

Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases
por: Xu, Jian‐ping, et al.
Publicado: (2016)

Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis
por: Qu, Jian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pf35nt3hlne64vdqbdtatrki6i